HGSI $10 more from yahoo board: Analysts who are less negative about the company's prospects for success in lupus say a positive study result could send the shares over $20. "In our view, this could be a tremendous opportunity if the data is positive," Citigroup analyst Yaron Werber recently told investors.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.